Table 2 –

Summary of trials included in meta-analysis with breakdown by Gleason grade group

Trial	Inclusion a	Number of patients randomized	Number of patients extracted	Arms	GG 4	GG 5	Total
RTOG 8531 (1987–1992)	cT1-T2N+ or cT3–4 <25 cm2 b	977	216	RT alone	61	47	108
				Lifelong ADT	59	49	108
RTOG 8610 (1987–1991)	cT2-T4 ≥25 cm2	456	128	RT alone	33	36	69
				STADT	29	30	59
RTOG 9202 (1992–1995)	cT2–4N0-X, PSA <150c	1554	337	STADT	93	78	171
				LTADT	92	74	166
EORTC 22863 (1987–1995)	cT1–2N0 WHO grade 3 cT3–4N0	415	43d	RT alone	17	7	24
				LTADT	13	6	19
EORTC 22961 (1997–2001)	cT1c-2bN+, cT3– 4N0 PSA <40 × ULN	970	186	STADT	56	34	90
				LTADT	75	21	96
EORTC 22991 (2001–2008)	cT1b-c with PSA ≥10 or GS ≥7, cT2a with PSA ≤50	819	82	RT alone	29	8	37
				STADT	36	9	45
				Group	GG 4	GG 5	Total
				RT alone	140	98	238
				STADT	214	151	365
				LTADT	180	101	281
				Lifelong ADT	59	49	108
				Total	593	399	992

ADT = androgen deprivation therapy; GG = Gleason grade group; GS = Gleason score; LTADT = long-term ADT; PSA = prostate-specific antigen; RT = radiation therapy; STADT = short-term ADT; ULN = upper limit of normal; WHO = World Health Organization.

^aPatients with cN+ or pN+ disease were included in several protocols but not included in our analyses.

^bRTOG 8531 also included patients with high-risk features after radical prostatectomy, who were not included in our analysis.

^cPSA values are in units of ng/ml unless otherwise indicated.

^dThe 43 patients from EORTC 22863 are drawn from a subgroup of 132 patients who underwent Gleason grading.